Before you can access ASH's online program, you must agree to the following:
Last updated January 16, 2009. Please note that this site represents the latest program changes
and differs from the print version in some details.

721.O2.8 Clinical Transplantation - Transplantation Regimen Toxicities and Engraftment 2

Tuesday, December 9, 2008: 7:00 AM-9:00 AM
2002-2004 - West (Moscone Center)
Moderators:
Arnon Nagler and Attaphol Pawarode, MD
7:00 AM
Reduced Intensity Versus Conventional Myeloablative Conditioning (RIC vs. MAC) Allogeneic Stem Cell Transplantation (allo-SCT) for Patients with Acute Lymphoblastic Leukemia (ALL): A Survey from the Acute Leukemia Working Party of EBMT

Mohamad Mohty, MD, PhD1, Myriam Labopin2*, Tapani Ruutu3, Alois Gratwohl4*, Gerard Socie5*, Jordi Esteve, MD6, Reza Tabrizi, MD7, Arnon Nagler8 and Vanderson Rocha9*

1Hematology Dept., CHU de Nantes, Nantes, France
2EBMT Paris Office, Paris, France
3Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland
4University Hospital of Basel, Basel, Switzerland
5Haematology, Hopital Saint-Louis
6Hematology, Hospital Clinic of Barcelona, Barcelona, Spain
7Hematology, Hopital Haut-Leveque - SFGMTC, Pessac, France
8Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Tel Hashomer, Israel
9BMT unit, Hopital Saint Louis APHP and Université Paris VII, Paris, France

7:15 AM
Second Unrelated Donor (URD) Transplant as a Rescue Strategy for 122 Patients with Primary Non Engraftment:  Results from the CIBMTRClinically Relevant Abstract

Jeffrey R. Schriber, MD1, Manza- A Agovi, MPH2*, Karen K Ballen, MD3, Andrea Bacigalupo, MD4, Gregory A. Hale, MD5, Vikas Gupta, MD, MRCP, MRCPath6, Hillard M. Lazarus, MD7, Mark R. Litzow, MD8, David I. Marks, MD9*, Roger H. Giller, MD10, Richard T. Maziarz, MD11, Martin Bornhauser, MD12*, Luis M. Isola, MD13*, Christopher Bredeson, MD14 and J. Douglas Rizzo, MD, MS2*

1Banner Good Samaritan Med. Ctr., Phoenix, AZ
2Medical College of Wisconsin, Center for International Blood and Marrow Transplant Research, Milwaukee, WI
3Massachusetts General Hospital, Boston, MA
4Hem-Onc, Ospedale S. Martino, Genova, Italy
5St. Jude Children's Research Hospital, Memphis, TN
6Princess Margaret Hospital, Toronto, ON, Canada
7University Hospitals Case Medical Center, Cleveland, OH
8Mayo Clinic, Rochester, MN
9Bristol Royal Hospital for Children, Bristol, United Kingdom
10The Children's Hospital, Aurora, CO
11Oregon Health & Science University, Portland, OR
12University Hospital Dresden, Dresden, Germany
13Mount Sinai Medical Center, New York, NY
14Medical College of Wisconsin, Milwaukee, WI

7:30 AM
Fludarabine Exposure Is Associated with Increased Treatment Related Mortality after Nonmyeloablative Hematopoietic Cell Transplantation (HCT)

Pamala A. Jacobson, PharmD1, Janel R Long, PharmD2*, John Rogosheske, PharmD3*, Kathleen Green, PharmD3*, Claudio Brunstein, MD4*, John E Wagner, MD5*, Qing Cao, MS6*, Jeffrey S. Miller, MD4, Philip McGlave, MD4* and Daniel Weisdorf, MD4

1Experimental and Clinical Pharmacology, University of Minnesota, Minneapolis, MN
2Experimental and Clinical Pharmacology, College of Pharmacy, Minneapolis, MN
3Department of Pharmacy, University of Minnesota Medical Center, Minneapolis, MN
4Hematology, Oncology, Transplantation, University of Minnesota, Minneapolis, MN
5Pediatric Hematology, Oncology, Transplantation, University of Minnesota, Minneapolis, MN
6Biostatistics and Informatics Core-Masonic Cancer Center, University of Minnesota, Minneapolis, MN

7:45 AM
Age-Dependent Pharmacokinetic Profile of Single Daily Dose Intravenous Busulfan in Children Undergoing Reduced-Intensity Conditioning Stem Cell Transplantation

William T. Tse, MD, PhD, Reggie Duerst, MD, Jennifer Schneiderman, MD, MS*, Sonali Chaudhury, M.D.*, David Jacobsohn, MD and Morris Kletzel, MD

Stem Cell Transplant Program, Division of Hematology-Oncology-Transplant, Children's Memorial Hospital, Northwestern University Feinberg School of Medicine, Chicago, IL

8:00 AM
Thrombotic Microangiopathy with Tacrolimus/Sirolimus-Based GVHD Prophylaxis Regimen in Patients Undergoing Hematopoietic Stem Cell Transplant from a Matched Unrelated Donor

Tam Khuu, PharmD1*, Sepideh Shayani, PharmD1*, Joycelynne Palmer, PhD2*, Roberto Rodriguez, MD3, Pablo Miguel Parker4, David S. Snyder, MD4, Vinod Pullarkat4, Joseph Rosenthal4, Auayporn P. Nademanee4, David Senitzer, PhD4, Ryotaro Nakamura, MD4 and Stephen J. Forman4

1Pharmacy Department, City of Hope National Medical Center, Duarte, CA
2Department of Information Sciences, City of Hope National Medical Center, Duarte, CA
3Oncology/Hematology, Kaiser Parmanente, Los Angeles, CA
4Division of Hematology/HCT, City of Hope National Medical Center, Duarte, CA

8:15 AM
Comparative Assessment of Weighting Comorbidities in the Hematopoietic Cell Transplantation (HCT) Specific Comorbidity Index (HCT-CI)

Todd E DeFor, MS1*, Navneet S. Majhail, MD, MS2, Claudio Brunstein, MD, PhD2, Daniel J. Weisdorf, MD2 and Chap T Le, PhD3*

1Cancer Center, University Of Minnesota, Minneapolis, MN
2University of Minnesota, Minneapolis, MN
3Biostatistics, University of Minnesota, Minneapolis, MN

8:30 AM
Busulfan and Fludarabine Conditioning Regimen Negates the Impact of Comorbidity Score on Nonrelapse Mortality in Patients with AML/MDS

Uday Popat, MD1, Rima Saliba, PhD1*, Leandro de Padua Silva, MD1, Borje S Andersson, MD, PhD2, Amin M Alousi, MD1, Paolo Anderlini, MD1, Marcos de Lima, MD1*, Grace-Julia Okoroji, MS, BS1*, Chitra M Hosing, MD1*, Roy B Jones, MD, PhD1*, Partow Kebriaei, MD1*, Issa Khouri, MD1*, Yago Nieto, MD, PhD1, Muzaffar H Qazilbash, MD1*, Richard Champlin, MD1 and Sergio A Giralt, MD1

1Stem Cell Transplantation and Cellular Therapy, University of Texas M.D. Anderson Cancer Center, Houston, TX
2Stem Cell Transplantation and Cellular Therapy, The University of Texas M. D. Anderson Cancer Center, Houston, TX

8:45 AM
Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) Is Accompanied by Endotoxemia, Activation of Endotoxin-Directed Innate Immunity, and Deficiency of Endogenous Proteins That Limit Endotoxin-Induced TNF Production

Ofer Levy, MD, PhD1, Eugenie E. Suter, MA1*, Leslie A. Kalish, PhD2*, Leighanne C. Gallington, SB1*, Athmane Teghanemt, MA3*, Suganya Viriyakosol, PhD4*, Robert J. Soiffer, MD5, Jerrold Weiss, PhD3*, Patrick Scannon, MD, PhD6*, Hoi M. Leung, PHD6*, Gregory Priebe, MD7*, Janice Russell, BS8*, Paul Walker, MD9*, Michael R. Wessels, MD1* and Eva Guinan, MD8

1Division of Infectious Diseases, Children's Hospital - Boston, Boston, MA
2Clinical Research Program, Children's Hospital - Boston, Boston, MA
3Department of Medicine, University of Iowa
4Department of Medicine, University of California, San Diego
5Hematologic Malignancies, Dana-Farber Cancer Inst., Boston, MA
6XOMA (U.S.) L.L.C., Berkeley, CA
7Division of Critical Care Medicine, Children's Hospital - Boston, Boston, MA
8Pediatric Oncology, Dana-Farber Cancer Inst, Boston, MA
9Spectral Diagnostics, Toronto, ON, Canada

*signifies non-member of ASH